Search results
Patricia M. LoRusso, DO, PhD (hc), began her medical career in early-phase clinical trial development to test new cancer therapies. Thirty years later, this American Association for Cancer Research ® (AACR) president is still conducting early-phase clinical trials to test novel ways to treat cancer.
Jun 18, 2014 · Patricia M. LoRusso, DO, widely-regarded as a leading expert on developing new cancer drugs through clinical trials, will join Yale Cancer Center in August as a Professor of Medicine and Associate Director of Innovative Medicine at Yale Cancer Center.
- 333 Cedar Street, New Haven, 06520, CT
May 3, 2024 · Dr. LoRusso uses the word “phenomenal” to describe the leap forward in cancer research enabled by the groundbreaking work on the human genome, new lab technologies and computational advancements.
- Naedine Hazell
- 333 Cedar Street, New Haven, 06520, CT
Patricia M. LoRusso, D.O., a leading expert on developing new cancer drugs through clinical trials, joined Yale Cancer Center in August as a professor of medicine and associate director of innovative medicine.
- 333 Cedar Street, New Haven, 06520, CT
Dec 15, 2023 · First person profile: Patricia M. LoRusso, DO. This researcher and clinician has conducted work in early-phase trials that has led to the approval of several anticancer agents, all while keeping her focus on the patients she says make these trials possible.
- Mary Beth Nierengarten
- 129, Issue24
- 15 December 2023
Sep 25, 2020 · In the subset of patients with COVID-19 receiving respiratory (venovenous) ECMO and characterised as having acute respiratory distress syndrome, the estimated cumulative incidence of in-hospital mortality 90 days after the initiation of ECMO was 38·0% (95% CI 34·6–41·5). Interpretation.
Jun 9, 2021 · Over the course of the COVID-19 pandemic, the care of patients with COVID-19 has changed and the use of extracorporeal membrane oxygenation (ECMO) has increased. We aimed to examine patient selection, treatments, outcomes, and ECMO centre characteristics over the course of the pandemic to date.
